We are live on ! Find out more
SAGE

Sage Therapeutics
SAGE

Delisted

SAGE was delisted on the 30th of July, 2025.

Back to rankings

224 hedge funds and large institutions have $2.54B invested in Sage Therapeutics in 2023 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 72 increasing their positions, 76 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 18

30% more call options, than puts

Call options by funds: $21.6M | Put options by funds: $16.6M

14% more capital invested

Capital invested by funds: $2.22B → $2.54B (+$321M)

6% more funds holding

Funds holding: 212 → 224 (+12)

1.99% more ownership

Funds ownership: 88.53% → 90.53% (+2%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

5% less repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 76

Holders
224
Holders Change
+12
Holders Change %
+5.66%
% of All Funds
3.52%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
31
Increased
72
Reduced
76
Closed
18
Calls
$21.6M
Puts
$16.6M
Net Calls
+$4.98M
Net Calls Change
-$3.09M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$84.9M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$32.3M
3
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$31.7M
4
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$29.5M
5
JP Morgan Chase
JP Morgan Chase
New York
+$15.8M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$41.2M
2
Marshall Wace
Marshall Wace
United Kingdom
-$30.5M
3
BlackRock
BlackRock
New York
-$25.2M
4
State Street
State Street
Massachusetts
-$21.7M
5
Goldman Sachs
Goldman Sachs
New York
-$21.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$413M +$84.9M +1,706,204 +24%
Wellington Management Group
2
Wellington Management Group
Massachusetts
$299M +$32.3M +649,207 +11%
Vanguard Group
3
Vanguard Group
Pennsylvania
$237M +$2.62M +52,666 +1%
BlackRock
4
BlackRock
New York
$208M -$25.2M -505,580 -10%
BG
5
Bellevue Group
Switzerland
$146M +$1.21M +24,375 +0.8%
State Street
6
State Street
Massachusetts
$108M -$21.7M -435,233 -16%
Dimensional Fund Advisors
7
Dimensional Fund Advisors
Texas
$80.7M +$3.06M +61,568 +4%
JP Morgan Chase
8
JP Morgan Chase
New York
$79.6M +$15.8M +317,276 +23%
BC
9
Boxer Capital
California
$51.4M – – –
T. Rowe Price Associates
10
T. Rowe Price Associates
Maryland
$50.8M -$41.2M -828,238 -43%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$50.2M +$1.36M +27,300 +3%
Deutsche Bank
12
Deutsche Bank
Germany
$48.7M +$12.8M +257,328 +33%
Ameriprise
13
Ameriprise
Minnesota
$41.8M -$11.7M -234,775 -21%
PAI
14
Palo Alto Investors
California
$40.4M – – –
Lord, Abbett & Co
15
Lord, Abbett & Co
New Jersey
$38.9M +$31.7M +637,244 +335%
Marshall Wace
16
Marshall Wace
United Kingdom
$37.5M -$30.5M -613,381 -43%
Northern Trust
17
Northern Trust
Illinois
$29.9M +$1.98M +39,871 +7%
PAMS
18
Pictet Asset Management (Switzerland)
Switzerland
$28.2M +$29.5M +592,380 +9,061%
Manulife (Manufacturers Life Insurance)
19
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$27.9M -$1.53M -30,733 -5%
Goldman Sachs
20
Goldman Sachs
New York
$24.1M -$21.6M -434,173 -46%
AG
21
Artal Group
Luxembourg
$23.5M -$12.4M -250,000 -33%
D.E. Shaw & Co
22
D.E. Shaw & Co
New York
$21.2M +$151K +3,037 +0.7%
Fisher Asset Management
23
Fisher Asset Management
Washington
$20.3M +$509K +10,229 +2%
Millennium Management
24
Millennium Management
New York
$19.7M +$2.56M +51,447 +14%
Norges Bank
25
Norges Bank
Norway
$18.4M – – –
1
2 3 4 5

SAGE Hedge Fund Activity: Q2 2023 in Review

224 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q2 2023, worth a combined $2.54B — up 14% from $2.22B a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new SAGE positions and 18 closed out — a net gain of 13 holders — while 72 added to existing stakes and 76 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $84.9M. The largest seller was T. Rowe Price Associates, cutting an estimated $41.2M.

  • 224 institutional investors held Sage Therapeutics (SAGE) as of Q2 2023, up from 212 in Q1 2023.
  • Funds reported $2.54B of Sage Therapeutics stock for Q2 2023, up 14% quarter-over-quarter.
  • 31 funds opened new Sage Therapeutics positions in Q2 2023 and 18 closed out, a net change of +13 holders.
  • The largest Sage Therapeutics buyer in Q2 2023 was Fidelity Investments, an estimated $84.9M added.
  • The largest Sage Therapeutics seller in Q2 2023 was T. Rowe Price Associates, an estimated $41.2M sold.

Based on aggregated 13F filings for Q2 2023.